Pomerantz Law Firm Investigates Immutep Limited for Potential Securities Fraud
Pomerantz LLP is investigating Immutep Limited (NASDAQ: IMMP) for potential securities fraud following the discontinuation of its TACTI-004 Phase III trial. The company's ADR price dropped by 82.44% to $0.48 on March 13, 2026, after the trial was halted due to futility. The investigation could lead to legal action against the company and its officers.
Tickers: $IMMP
Topics: class action clinical trial discontinuation investor relations securities fraud stock price drop